| Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 | 8794 | 2015 |
| The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ... Journal of Thoracic Oncology 11 (1), 39-51, 2016 | 3978 | 2016 |
| Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. TIALCTC Group N Engl J Med 350, 351-360, 2004 | 2996* | 2004 |
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial R Pirker, JR Pereira, A Szczesna, J von Pawel, M Krzakowski, R Ramlau, ... The Lancet 373 (9674), 1525-1531, 2009 | 1810 | 2009 |
| Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials … L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ... Journal of clinical oncology 35 (35), 3924, 2017 | 854 | 2017 |
| EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 … R Pirker, JR Pereira, J Von Pawel, M Krzakowski, R Ramlau, K Park, ... The lancet oncology 13 (1), 33-42, 2012 | 682 | 2012 |
| Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up J Vansteenkiste, D De Ruysscher, WEE Eberhardt, E Lim, S Senan, ... Annals of oncology 24, vi89-vi98, 2013 | 639 | 2013 |
| The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth … WD Travis, H Asamura, AA Bankier, MB Beasley, F Detterbeck, DB Flieder, ... Journal of Thoracic Oncology 11 (8), 1204-1223, 2016 | 615 | 2016 |
| Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial C Butts, MA Socinski, PL Mitchell, N Thatcher, L Havel, M Krzakowski, ... The lancet oncology 15 (1), 59-68, 2014 | 549 | 2014 |
| The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer WEE Eberhardt, A Mitchell, J Crowley, H Kondo, YT Kim, A Turrisi III, ... Journal of thoracic oncology 10 (11), 1515-1522, 2015 | 543 | 2015 |
| 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ... Annals of Oncology 25 (8), 1462-1474, 2014 | 537 | 2014 |
| Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial RS Herbst, Y Sun, WEE Eberhardt, P Germonpré, N Saijo, C Zhou, ... The lancet oncology 11 (7), 619-626, 2010 | 499 | 2010 |
| Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial K Kelly, NK Altorki, WEE Eberhardt, MER O'Brien, DR Spigel, L Crinò, ... Journal of Clinical Oncology 33 (34), 4007-4014, 2015 | 485 | 2015 |
| Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, JC Carpeno, ... Journal of Clinical Oncology 39 (7), 723-733, 2021 | 417 | 2021 |
| Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small … W Eberhardt, H Wilke, G Stamatis, M Stuschke, A Harstrick, H Menker, ... Journal of clinical oncology 16 (2), 622-634, 1998 | 409 | 1998 |
| The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer K Chansky, FC Detterbeck, AG Nicholson, VW Rusch, E Vallières, ... Journal of Thoracic Oncology 12 (7), 1109-1121, 2017 | 405 | 2017 |
| 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer WEE Eberhardt, D De Ruysscher, W Weder, C Le Pechoux, P De Leyn, ... Annals of Oncology 26 (8), 1573-1588, 2015 | 402 | 2015 |
| International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. International Association for … P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ... J Thorac Oncol 11 (1), 39-51, 2016 | 397 | 2016 |
| The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung … AG Nicholson, K Chansky, J Crowley, R Beyruti, K Kubota, A Turrisi, ... Journal of Thoracic Oncology 11 (3), 300-311, 2016 | 377 | 2016 |
| Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer KM Kerr, L Bubendorf, MJ Edelman, A Marchetti, T Mok, S Novello, ... Annals of Oncology 25 (9), 1681-1690, 2014 | 360 | 2014 |
Scott J AntoniaПідтверджена електронна адреса в duke.edu
